Open AccessImpact of adjuvant intrabladder therapy on quality of life in patients, suffering musculo-noninvasive cancer of the bladder
Author(s) -
F.I. Kostyev,
О. V. Bondar,
Roman Chystiakov,
В. В. Лысенко
Publication year - 2020
Publication title -
klìnìčna hìrurgìâ/klìnìčna hìrurgìâ
Language(s) - English
Resource type - Journals
eISSN - 2522-1396
pISSN - 0023-2130
DOI - 10.26779/2522-1396.2020.7-8.47
Subject(s) - medicine , quality of life (healthcare) , adjuvant , chemotherapy , immunotherapy , bladder cancer , cancer , surgery , oncology , physical therapy , nursing
Objective. Comparative estimation of quality of life in patients with a high-risk musculo-noninvasive cancer of the bladder was accomplished while conduction of adjuvant intrabladder hyperthermic chemotherapy and immunotherapy with BCG vaccine.
Маterials and methods. Depending on kind of treatment, the patients were distributed into two groups: Group I - 44 patients, to whom adjuvant intrabladder immunotherapy with BCG vaccine was applied, and Group II - 41 patients, to whom intrabladder chemotherapy was conducted, using the system for local hyperthermy Combat BRS.
Results. The data from the patients interviewed, using EORTC QLQ-30 questionnaires, confirmed better quality of life in patients of Group II, who obtained intrabladder hyperthermic chemotherapy, peculiarly in accordance to indices of physical status, social adaptation and intoxication. In accordance to data of the patients’ interviewed with the help of FACT-BL questionnaire, also better results were obtained in patients of Group II in accordance to the social and functional well-being status, the urination quality and values of indices of the «Cancer of the Bladder» scale.
Conclusion. Higher quality of life was noted in patients of Group II, who obtained intrabladder hyperthermic chemotherapy. The lower quality of life in patients of Group I, who obtained immunotherapy with BCG vaccine, was connected with multiple side effects and enhanced toxicity of this therapy, accordingly.